â– LECTURE OVERVIEW: Schizophrenia is a chronic, heterogeneous psychiatric disorder characterized by a disintegration of thought processes and emotional responsiveness.
â– DOPAMINERGIC PATHWAYS & RECEPTORS:
1. Positive Symptoms (Excess/distortion of normal function):
- Manifestations: Hallucinations, delusions, disorganized speech, and grossly disorganized behavior.
- Pathway: Driven by dopamine hyperactivity at D2 receptors selectively in the Mesolimbic pathway of the brain.
2. Negative Symptoms (Loss of normal function):
- Manifestations: Apathy, flat affect, alogia (poverty of speech), anhedonia, and social withdrawal.
- Pathway: Driven by relative dopamine hypoactivity at D1 receptors in the Mesocortical pathways.
â– HISTOMEDICAL INTEGRATIVE MICROSPECTRA:
Ultrastructural analysis of target tissue reveals altered organelle density, high-yield ribosomal tagging, changes in basement membrane integrity, and specialized junction breakdown associated with functional deterioration.
â– ACUTE TOXICOLOGICAL PROFILE:
High cumulative chemical exposure or accidental overdose triggers systemic receptor overload, cellular injury, and metabolic acidosis.
[HY-BOARD-1171]
🌟 Dynamic Clinical Key:
First-generation antipsychotics (e.g., Haloperidol, Chlorpromazine) are potent D2 blockers that treat positive symptoms but can worsen negative symptoms and cause extrapyramidal side effects. Second-generation atypical antipsychotics (e.g., Aripiprazole, Clozapine, Olanzapine) block 5-HT2A receptors alongside D2, offering better management of negative symptoms. Look for pathognomonic electron microscopy structures (e.g., zebra bodies, Birbeck granules) for confirmation of metabolic storage diseases. Immediate administration of physiological charcoal or specific receptor antagonists is lifesaving.